TIPS treatment support for liver cancer patients on Atezo + Bev
Part of Cancer, Digestive system clinical trials.
This study looks at whether adding TIPS (a procedure to reduce fluid buildup) to standard immunotherapy (atezolizumab and bevacizumab) helps people with advanced liver cancer who also have cirrhosis. It's for patients whose cancer cannot be removed by surgery or has progressed after other local treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC) that has spread or cannot be removed by surgery.
- You have liver cirrhosis (scarring of the liver).
- Your doctor has already decided to treat you with atezolizumab and bevacizumab (with or without TIPS).
- You can start or have already had 1-2 cycles of this drug combination.
- You are 18 years or older.
- You can understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (TPST-1120, atezolizumab, and bevacizumab) for people with advanced liver cancer that hasn't been treated before. The goal is to see if adding this new drug to the standard immunotherapy and targeted therapy helps shrink or control the cancer better.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer in real life, outside of a clinical trial. It will help doctors understand the treatment's benefits and risks based on patient records.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.